Core Insights - Elicio Therapeutics has reported preliminary findings from the Phase 2 AMPLIFY-7P trial, indicating that specific Human Leukocyte Antigen (HLA) types do not affect the ability of patients to generate robust mKRAS-specific T-cell responses after treatment with ELI-002 7P [1][3][5] Group 1: Trial Findings - Among 89 patients treated with ELI-002 7P, a total of 1,132 unique HLAs were identified, demonstrating significant genetic diversity within the study population [2][5] - 99% (88 out of 89) of patients assessed for HLA background showed mKRAS-specific T-cell responses post-treatment, suggesting broad applicability of ELI-002 7P for pancreatic ductal adenocarcinoma (PDAC) patients [5][6] - The findings align with recent studies indicating that mKRAS antigens can be presented across a wide range of HLA types, supporting the potential for ELI-002 7P to address a critical unmet need in cancer treatment [2][3] Group 2: Product and Technology Overview - Elicio's lead product candidate, ELI-002, is an off-the-shelf immunotherapy targeting common KRAS mutations, which are responsible for approximately 25% of all solid tumors [4][7] - The AMP technology utilized in ELI-002 aims to enhance the activation and amplification of cancer-specific T cells, potentially leading to durable cancer immunosurveillance [4][9] - Elicio plans to expand the application of ELI-002 to other indications, including mKRAS-positive lung cancer and additional mKRAS-driven cancers, indicating a broad pipeline of therapeutic candidates [6][8]
Elicio Therapeutics Reports Robust T cell Responses Across Diverse HLA backgrounds in Ongoing Phase 2 AMPLIFY-7P Trial